Antiplatelet drugs and liver fibrosis

Abstract Liver fibrosis results from an imbalance between extracellular matrix formation and degradation. The background of liver fibrosis is chronic inflammation and subsequent microcirculation disturbance including microthrombosis. Platelets actively participate in liver fibrosis not only as a part of the clotting system but also by releasing granules containing important mediators. In fact, platelets may play a dual role in the pathophysiology of liver fibrosis as they are able to stimulate regeneration as well as aggravate the destruction of the liver. Recent studies revealed that antiplatelet therapy correlates with inhibition of liver fibrosis. However, liver impairment is associated with extensive coagulation disorders thus the safety of antiplatelet therapy is an area for detailed exploration. In this review, the role of platelets in liver fibrosis and accompanying hemostatic disorders are discussed. Additionally, results of animal and human studies on antiplatelet drugs in liver disorders and their potential therapeutic utility are presented.

• Publication year

  2021

• Venue

  Platelets

• Publication date

  2021-02-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/09537104.2021.1883574PMID 33577391
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis

  2020cited by this paper
• Advances in non-invasive assessment of hepatic fibrosis

  2020cited by this paper
• Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease

  2020cited by this paper
• Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology

  2020cited by this paper
• Not all (N)SAID and done: Effects of nonsteroidal anti‐inflammatory drugs and paracetamol intake on platelets

  2019cited by this paper
• AGA Clinical Practice Update: Coagulation in Cirrhosis.

  2019cited by this paper
• Disease Burden of Hepatocellular Carcinoma: A Global Perspective

  2019cited by this paper
• Routine Use of Vitamin K in the Treatment of Cirrhosis-Related Coagulopathy: Is it A-O-K? Maybe Not, We Say.

  2019cited by this paper
• Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L‐PLUS 2)

  2019cited by this paper
• Effect of low-dose aspirin administration on long-term survival of cirrhotic patients after splenectomy: A retrospective single-center study

  2019cited by this paper
• Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma

  2019cited by this paper
• Interruption of platelets and thrombin function as a new approach against liver fibrosis induced experimentally in rats.

  2019cited by this paper
• Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities

  2019cited by this paper
• Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection.

  2019cited by this paper
• Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures

  2019cited by this paper
• Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease.

  2019cited by this paper
• Platelets and Platelet‐Derived Extracellular Vesicles in Liver Physiology and Disease

  2019cited by this paper
• Pro: Noninvasive Imaging Has Replaced Biopsy as the Gold Standard in the Evaluation of Nonalcoholic Fatty Liver Disease

  2019cited by this paper
• Anticoagulation Therapy in Patients with Liver Cirrhosis is Associated With an Increased Risk of Variceal Hemorrhage.

  2019cited by this paper
• Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.

  2019cited by this paper
• Role of platelet serotonin in innate immune cell recruitment.

  2019cited by this paper
• Dual antiplatelet therapy in patients with cirrhosis and acute myocardial infarction – A 13-year nationwide cohort study

  2019cited by this paper
• Perioperative thromboprophylaxis in liver transplant patients

  2018cited by this paper
• von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C

  2018cited by this paper
• Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults

  2018cited by this paper
• Platelet TGF-β1 deficiency decreases liver fibrosis in a mouse model of liver injury.

  2018cited by this paper
• Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.

  2018cited by this paper
• Association Between Aspirin Use and Risk of Hepatocellular Carcinoma

  2018cited by this paper
• Ticagrelor – toward more efficient platelet inhibition and beyond

  2018influential reference
• Regular aspirin use is not protective against advanced fibrosis in type-2 diabetics with biopsy-proven nonalcoholic fatty liver disease

  2018cited by this paper
• Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease

  2018cited by this paper
• Use of Antiplatelet Agents Is Inversely Associated With Liver Fibrosis in Patients With Cardiovascular Disease

  2018influential reference
• Effects of early antiplatelet therapy after splenectomy with gastro‐oesophageal devascularization

  2018cited by this paper
• The risk of lower gastrointestinal bleeding in low‐dose aspirin users

  2017cited by this paper
• Patients with cirrhosis who have coronary artery disease treated with cardiac stents have high rates of gastrointestinal bleeding, but no increased mortality

  2017cited by this paper
• Diagnostic Accuracy of Platelet Count and Platelet Indices in Noninvasive Assessment of Fibrosis in Nonalcoholic Fatty Liver Disease Patients

  2017influential reference
• Liver sinusoidal endothelial cells: Physiology and role in liver diseases.

  2017cited by this paper
• Liver inflammation and fibrosis.

  2017cited by this paper
• Platelets in liver disease, cancer and regeneration

  2017cited by this paper
• Endothelial damage effects of circulating microparticles from patients with stable angina are reduced by aspirin through ERK/p38 MAPKs pathways

  2017cited by this paper
• Effects of aspirin and enoxaparin in a rat model of liver fibrosis

  2017cited by this paper
• Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy

  2016cited by this paper
• Novel functions of platelets in the liver

  2016cited by this paper
• Aspirin use is associated with lower indices of liver fibrosis among adults in the United States

  2016cited by this paper
• Acute Middle Gastrointestinal Bleeding Risk Associated with NSAIDs, Antithrombotic Drugs, and PPIs: A Multicenter Case-Control Study

  2016cited by this paper
• COX-2, aspirin and metabolism of arachidonic, eicosapentaenoic and docosahexaenoic acids and their physiological and clinical significance.

  2016cited by this paper
• Platelets: No longer bystanders in liver disease

  2016cited by this paper
• The PDGF system and its antagonists in liver fibrosis.

  2016cited by this paper
• Coagulopathy in liver disease: Lack of an assessment tool.

  2015cited by this paper
• Incidence of Bleeding in 8172 Percutaneous Ultrasound-Guided Intraabdominal Diagnostic and Therapeutic Interventions – Results of the Prospective Multicenter DEGUM Interventional Ultrasound Study (PIUS Study)

  2015cited by this paper
• State-of-the-Art: Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus

  2015cited by this paper
• Lipoxins and aspirin-triggered lipoxins in resolution of inflammation.

  2015cited by this paper
• Platelets in leucocyte recruitment and function.

  2015cited by this paper
• Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model

  2015influential reference
• Coagulopathy in liver disease: a balancing act.

  2015cited by this paper
• International Survey on D-Dimer Test Reporting: A Call for Standardization

  2015cited by this paper
• Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice.

  2014cited by this paper
• Liver cirrhosis.

  2014cited by this paper
• Effects of Increased Von Willebrand Factor Levels on Primary Hemostasis in Thrombocytopenic Patients with Liver Cirrhosis

  2014cited by this paper
• Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation.

  2014cited by this paper
• Deep vein thrombosis and pulmonary embolism in cirrhotic patients: systematic review.

  2014cited by this paper
• Non-invasive diagnosis of advanced fibrosis and cirrhosis.

  2014cited by this paper
• Association of plasma concentrations of salicylic acid and high on ASA platelet reactivity in type 2 diabetes patients.

  2013cited by this paper
• Dual antiplatelet therapy in patients with diabetes mellitus: special considerations

  2013cited by this paper
• Pulmonary antifibrotic mechanisms aspirin-triggered lipoxin A(4) synthetic analog.

  2013cited by this paper
• Hepatocytes produce TNF-α following hypoxia-reoxygenation and liver ischemia-reperfusion in a NADPH oxidase- and c-Src-dependent manner.

  2013cited by this paper
• Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes.

  2013cited by this paper
• Secrets of platelet exocytosis – what do we really know about platelet secretion mechanisms?

  2013cited by this paper
• Hepatic sinusoidal endothelium avidly binds platelets in an integrin-dependent manner, leading to platelet and endothelial activation and leukocyte recruitment.

  2013cited by this paper
• Risk factors and clinical characteristics of portal vein thrombosis after splenectomy in patients with liver cirrhosis.

  2013influential reference
• Coagulation abnormalities in the cirrhotic patient.

  2013influential reference
• Early aspirin therapy may reduce hepatic artery thrombosis in liver transplantation.

  2013cited by this paper
• Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.

  2012cited by this paper
• Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.

  2012cited by this paper
• Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B

  2012cited by this paper
• Functional aspects on the pathophysiology of portal hypertension in cirrhosis.

  2012cited by this paper
• Aspirin for preventing the recurrence of venous thromboembolism.

  2012cited by this paper
• Effectiveness and safety of antiplatelet therapy in stroke recurrence prevention in patients with liver cirrhosis: a 2‐year follow‐up study

  2012cited by this paper
• Platelets and the immune continuum

  2011cited by this paper
• Platelets, inflammation and tissue regeneration

  2011cited by this paper
• Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease

  2011cited by this paper
• Noninvasive Evaluation of Liver Fibrosis in Patients with Chronic Hepatitis C

  2011cited by this paper
• Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension

  2011cited by this paper
• In Hepatic Fibrosis, Liver Sinusoidal Endothelial Cells Acquire Enhanced Immunogenicity

  2010cited by this paper
• Activation of human liver sinusoidal endothelial cell by human platelets induces hepatocyte proliferation.

  2010cited by this paper
• An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis.

  2009cited by this paper
• ATLa, an Aspirin-Triggered Lipoxin A4 Synthetic Analog, Prevents the Inflammatory and Fibrotic Effects of Bleomycin-Induced Pulmonary Fibrosis1

  2009cited by this paper
• Platelet functions beyond hemostasis

  2009cited by this paper
• Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease.

  2009cited by this paper
• Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation?

  2007cited by this paper
• Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A(2).

  2007cited by this paper
• Platelet-activating factor in liver injury: a relational scope.

  2006cited by this paper
• Activation of Platelet Function Through G Protein–Coupled Receptors

  2006cited by this paper
• Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity

  2006cited by this paper
• The Levels of Ghrelin, Leptin, TNF-α, and IL-6 in Liver Cirrhosis and Hepatocellular Carcinoma due to HBV and HDV Infection

  2006cited by this paper
• Hepatic platelet and leukocyte adherence during endotoxemia

  2006cited by this paper
• Role of thromboxane in producing hepatic injury during hepatic stress.

  2005cited by this paper
• Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation.

  2005cited by this paper
• Liver fibrosis.

  2005cited by this paper
• Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin.

  2004cited by this paper

• Novel Epitranscriptomic and Epigenetic Therapeutic Strategies and Targets for Ferroptosis in Liver Fibrosis.

  2025cites this paper
• Prorenin in Hepatic Stellate Cell Extracellular Vesicles Induces Platelet‐Dependent Thrombin Formation and Release of Profibrotic TGF‐β

  2025cites this paper
• The Platelet-Specific Gene Signature in the Immunoglobulin G4-Related Disease Transcriptome

  2025cites this paper
• Fibroblasts and platelets, a face-to-face dialogue at the heart of cardiac fibrosis.

  2024cites this paper
• Clopidogrel ameliorates high-fat diet-induced hepatic steatosis in mice through activation of the AMPK signaling pathway and beyond

  2024cites this paper
• Impact of concomitant cardiovascular medications on overall survival in patients with liver cirrhosis

  2023cites this paper
• Effects of thrombopoietin pre-treatment on peri-liver transplantation thrombocytopenia in a mouse model of cirrhosis with hypersplenism

  2023cites this paper
• Probiotics and liver fibrosis: An evidence-based review of the latest research

  2023cites this paper
• Various types of adenomyosis and endometriosis: In search of optimal management.

  2023cites this paper
• Computational drug repositioning of clopidogrel as a novel therapeutic option for focal segmental glomerulosclerosis.

  2023cites this paper
• The Important Roles of Natural Killer Cells in Liver Fibrosis

  2023cites this paper
• Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications

  2023cites this paper
• The Therapeutic Potential of Anticoagulation in Organ Fibrosis

  2022cites this paper
• Nonalcoholic fatty liver disease and cardiovascular concerns: The time for hepatologist and cardiologist close collaboration

  2021cites this paper